 |
 |
 |
| 24小時(shí)熱門版塊排行榜 |
- >論壇更新日志 (913)
- >考研 (173)
- >導(dǎo)師招生 (96)
- >蟲(chóng)友互識(shí) (38)
- >考博 (25)
- >文獻(xiàn)求助 (24)
- >論文投稿 (22)
- >博后之家 (14)
- >文獻(xiàn)求助完結(jié)子版 (14)
- >碩博家園 (13)
- >找工作 (12)
- >論文道賀祈福 (8)
- >基金申請(qǐng) (8)
- >教師之家 (4)
- >招聘信息布告欄 (3)
- >科研資料 (3)
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 2068 | 回復(fù): 12 | ||||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | ||||
zlwcw木蟲(chóng) (著名寫手)
|
[交流]
50 M 華醫(yī)獲得第一桶金 已有6人參與
|
|||
|
http://www.msnbc.msn.com/id/4459 ... -commercialization/ 上海--(美國(guó)商業(yè)資訊)--作為中國(guó)領(lǐng)先的藥物創(chuàng)新研發(fā)和發(fā)展公司，華醫(yī)藥今天宣布在由ChinaBio® LLC和蘇州BioBay共同舉辦的BioBay 創(chuàng)業(yè)投資論壇的協(xié)助下，公司獲得一批美國(guó)和中國(guó)著名醫(yī)療投資公司5千萬(wàn)美元的融資承諾。這些投資公司有ARCH 風(fēng)險(xiǎn)投資合作公司，富達(dá)生命科學(xué)，富達(dá)亞洲風(fēng)險(xiǎn)投資，Venrock，Sino-Alliance International Ltd和新興投資公司無(wú)錫藥明康達(dá)風(fēng)險(xiǎn)投資，這些基金將用于推進(jìn)華醫(yī)藥的內(nèi)部研發(fā)項(xiàng)目以及為其他項(xiàng)目的收購(gòu)，研發(fā)和發(fā)展提供資金支持。 中國(guó)生物制藥 (HK:01177)最新價(jià)：2.19 0.04 1.86%行情走勢(shì)公司新聞大行評(píng)級(jí) 無(wú)錫藥明康達(dá)財(cái)務(wù)總監(jiān)愛(ài)德華說(shuō)，無(wú)錫公司風(fēng)險(xiǎn)基金的設(shè)立主要是為像華醫(yī)藥這樣的公司提供資金支持，這些公司的精英領(lǐng)導(dǎo)者通過(guò)各種有效的合作研發(fā)創(chuàng)技術(shù)和產(chǎn)品，并將它們商業(yè)化。華醫(yī)藥所擁有的精英藥物研發(fā)團(tuán)隊(duì)，能夠同時(shí)開(kāi)展多個(gè)項(xiàng)目，從早期的研發(fā)項(xiàng)目，乃至獲得項(xiàng)目許可從而使產(chǎn)品順利在中國(guó)進(jìn)行商業(yè)化推廣。 華醫(yī)藥董事會(huì)成員以及富達(dá)亞洲風(fēng)險(xiǎn)投資管理伙伴丹尼爾 奧爾·巴赫說(shuō)："不像大多數(shù)新生生物技術(shù)公司需要十年或更長(zhǎng)的時(shí)間才能收益，華醫(yī)藥能夠利用其研發(fā)，管理和發(fā)展的專業(yè)資源，從一系列成熟項(xiàng)目中創(chuàng)造可觀的短期價(jià)值。我們非常高興華醫(yī)藥能有這樣的機(jī)遇，公司目前正同多個(gè)市政當(dāng)局探討在當(dāng)?shù)貫槲覀兊捻?xiàng)目建立更多的基礎(chǔ)設(shè)施。" 華醫(yī)藥首席執(zhí)行官陳力補(bǔ)充說(shuō)："華醫(yī)藥致力于建立一種更好的新方法，集合東西方之優(yōu)勢(shì)，研發(fā)新藥并將其商業(yè)化， 。我我們有幸能建立一個(gè)強(qiáng)大的團(tuán)隊(duì)，包括一些著名的醫(yī)療投資公司，例如新的公司投資者-作為中國(guó)生命科學(xué)領(lǐng)域領(lǐng)先企業(yè)的無(wú)錫藥明康達(dá)。 華醫(yī)藥的創(chuàng)始人包括陳力博士-羅氏研發(fā)中心前首席科學(xué)官；杰克 鮑德溫-默克-Trusopt的發(fā)現(xiàn)者以及Pharmacopeia and Vitae PharmaceuticaLS公司的創(chuàng)始人之一和科學(xué)主任；約翰蔡-來(lái)自Venrock；李革博士-無(wú)錫藥明康達(dá)創(chuàng)始人，總裁和首席執(zhí)行官；丹尼爾 奧爾·巴赫-富達(dá)亞洲富達(dá)亞洲風(fēng)險(xiǎn)投資管理伙伴；布萊恩 羅伯特-來(lái)自Venroc以及羅伯特尼爾森-ARCH Venture Partners創(chuàng)始人之一及常務(wù)董事。 關(guān)于華醫(yī)藥 華醫(yī)藥致力于成為中國(guó)一流的、著眼于世界市場(chǎng)的充分整合的生物技術(shù)公司。公司充分利用中國(guó)低成本但高質(zhì)量的新藥發(fā)現(xiàn)能力，并且同亞洲、美國(guó)和歐洲的非常有潛力的藥物資源進(jìn)行合作和授權(quán)許可交易。通過(guò)這些努力，華醫(yī)藥立志成為中國(guó)轉(zhuǎn)變?yōu)閲?guó)際藥物研發(fā)創(chuàng)新中心的驅(qū)動(dòng)力量。 關(guān)于BioBay創(chuàng)業(yè)投資論壇 第四屆年度BioBay創(chuàng)業(yè)投資論壇在中國(guó)蘇州舉辦。19家早期生命科學(xué)企業(yè)在會(huì)上向50多家投資公司作項(xiàng)目路演。會(huì)議由位于上海的咨詢和會(huì)議主辦公司ChinaBio® LLC和中國(guó)發(fā)展最快的生命科學(xué)園蘇州工業(yè)園區(qū)合辦。 SHANGHAI, CHINA — Hua Medicine, the leading innovative drug development and commercialization company in China, announced today that it has secured $50 million in new financing commitments from a prestigious group of US and Chinese healthcare investors, including ARCH Venture Partners, Fidelity Biosciences, Fidelity Growth Partners Asia, Venrock, Sino-Alliance International Ltd and new investor WuXi PharmaTech Corporate Venture. These funds are expected to progress Hua's internal development programs as well as provide financial resources for the acquisition, development and commercialization of additional programs. "WuXi's corporate venture fund was set up to fund companies like Hua Medicine that bring together great minds to develop and commercialize innovative technologies and products through fruitful collaborations," said Edward Hu, Chief Financial Officer of WuXi PharmaTech. "With an elite drug development team, Hua Medicine is well positioned to pursue multiple projects that cover the spectrum from early development programs to in-licensing of assets for successful commercialization in China." "Unlike most biotechnology start-ups which may take a decade or more to become profitable, Hua is in a position to utilize its development, regulatory and commercialization expertise to create substantial near-term value from a pipeline of late stage programs," said Hua Board Member Daniel Auerbach, Managing Partner of Fidelity Growth Partners Asia. "We are very excited about Hua's opportunities and the company is currently in discussions with a number of municipalities about establishing additional local facilities for our programs." Hua CEO Li Chen adds, "Hua is focused on building a new and better way to develop and commercialize drugs, leveraging the best of what the Eastern and Western worlds have to offer. We are fortunate to have a strong team that extends to a prominent group of healthcare investors, including new corporate investor, WuXi PharmaTech, the entrepreneurial leader in China's life sciences sector." Hua was co-founded by Dr. Li Chen, the former Chief Scientific Officer of Roche's R&D Center in China; Jack Baldwin, discoverer of Trusopt at Merck and Co-Founder and CSO of Pharmacopeia and Vitae Pharmaceuticals; John Choi, previously of Venrock; Dr. Ge Li, Founder, Chairman and CEO of WuXi PharmaTech; Daniel Auerbach, Managing Partner of Fidelity Growth Partners Asia; Bryan Roberts of Venrock; and Robert Nelsen, Co-Founder and Managing Director of ARCH Venture Partners. About Hua Medicine Hua is focused on becoming the leading, fully-integrated biotech company in China targeting world-wide markets. The company leverages the lower-cost yet highest-quality drug discovery capabilities available in China, while partnering or licensing the most promising drug assets from Asia, the US and EU. Through [ Last edited by zlwcw on 2011-9-25 at 11:49 ] |
回復(fù)此樓» 收錄本帖的淘帖專輯推薦
 經(jīng)典資源帖 |
» 猜你喜歡
26年博士申請(qǐng)
已經(jīng)有20人回復(fù)
-
廣西醫(yī)科大學(xué)基礎(chǔ)醫(yī)學(xué)院自身免疫病課題組招收基礎(chǔ)醫(yī)學(xué)相關(guān)專業(yè)的調(diào)劑研究生
已經(jīng)有2人回復(fù)
-
藥理學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有50人回復(fù)
-
求助 苯磷硫胺JP
已經(jīng)有0人回復(fù)
-
100金幣 阿莫西林克拉維酸鉀片BP藥典中提到的克拉維酸聚合物具體結(jié)構(gòu)式是啥？
已經(jīng)有2人回復(fù)
-
膳食補(bǔ)充劑合規(guī)性交流
已經(jīng)有0人回復(fù)
-
一志愿浙大藥學(xué)求調(diào)劑
已經(jīng)有1人回復(fù)
-
高溫高壓反應(yīng)求助
已經(jīng)有4人回復(fù)
-
藥學(xué)B區(qū)求調(diào)劑
已經(jīng)有0人回復(fù)
-
重慶醫(yī)科大學(xué)-人工智能醫(yī)學(xué)學(xué)院
已經(jīng)有0人回復(fù)
-
重慶醫(yī)科大學(xué)-人工智能醫(yī)學(xué)學(xué)院
已經(jīng)有0人回復(fù)
» 本主題相關(guān)商家推薦: (我也要在這里推廣)
» 本主題相關(guān)價(jià)值貼推薦，對(duì)您同樣有幫助:
- 鋁鐵合金冷軋50%算不算大變形，這個(gè)有什么鑒定標(biāo)準(zhǔn)嗎[/font]習(xí)
已經(jīng)有12人回復(fù)
- 做工藝技術(shù)的如何盡快的賺錢第一桶金
已經(jīng)有22人回復(fù)
- 【分享】第一桶金_改變命運(yùn)的68個(gè)創(chuàng)業(yè)傳奇PDF格式中文版[創(chuàng)業(yè)故事]【已搜索無(wú)重復(fù)】
已經(jīng)有5人回復(fù)
- 【轉(zhuǎn)帖】獲TPG投資尚華醫(yī)藥擬紐交所上市
已經(jīng)有7人回復(fù)
- 科研的第一桶金!
已經(jīng)有210人回復(fù)
藥道人
榮譽(yù)版主 (文壇精英)
凈由穢生，明從闇出
-
專家經(jīng)驗(yàn): +71 - DRDEPI: 1
- 應(yīng)助: 38 (小學(xué)生)
- 貴賓: 6.92
- 金幣: 27026.1
- 散金: 9994
- 紅花: 143
- 沙發(fā): 178
- 帖子: 25008
- 在線: 1356.1小時(shí)
- 蟲(chóng)號(hào): 336426
- 注冊(cè): 2007-04-01
- 性別: GG
- 專業(yè): 道教
- 管轄: 金融投資
9樓2011-09-29 12:34:38
藥道人
榮譽(yù)版主 (文壇精英)
凈由穢生，明從闇出
-
專家經(jīng)驗(yàn): +71 - DRDEPI: 1
- 應(yīng)助: 38 (小學(xué)生)
- 貴賓: 6.92
- 金幣: 27026.1
- 散金: 9994
- 紅花: 143
- 沙發(fā): 178
- 帖子: 25008
- 在線: 1356.1小時(shí)
- 蟲(chóng)號(hào): 336426
- 注冊(cè): 2007-04-01
- 性別: GG
- 專業(yè): 道教
- 管轄: 金融投資
2樓2011-09-26 10:22:54
1994yw
木蟲(chóng) (正式寫手)
- 應(yīng)助: 8 (幼兒園)
- 金幣: 1708.3
- 散金: 105
- 帖子: 646
- 在線: 79.5小時(shí)
- 蟲(chóng)號(hào): 1242523
- 注冊(cè): 2011-03-23
- 專業(yè): 藥物設(shè)計(jì)與藥物信息
3樓2011-09-26 13:07:26
hdang2003
木蟲(chóng) (著名寫手)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 3408.9
- 散金: 605
- 紅花: 2
- 帖子: 1038
- 在線: 273.9小時(shí)
- 蟲(chóng)號(hào): 337078
- 注冊(cè): 2007-04-02
- 性別: GG
- 專業(yè): 合成藥物化學(xué)
4樓2011-09-26 14:43:29
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 083000環(huán)境科學(xué)與工程調(diào)劑，總分281 +4 | 橙子（勝意） 2026-03-30 | 4/200 |
|
|---|---|---|---|---|
|
|
[考研] 本科211總分289，08工學(xué)真心求調(diào)劑 +3 | utopiaE 2026-03-30 | 3/150 |
|
|
[考研] 一志愿南昌大學(xué)324求調(diào)劑 +9 | hanamiko 2026-03-27 | 9/450 |
|
|
|
[考研] 367求調(diào)劑 +5 | 芋泥啵�！� 2026-03-28 | 5/250 |
|
|
|
[考研] 327求調(diào)劑 +5 | 小卡不卡. 2026-03-29 | 5/250 |
|
|
|
[考研] 求調(diào)劑 +10 | 家佳佳佳佳佳 2026-03-29 | 10/500 |
|
|
|
[考研] 328求調(diào)劑 +8 | 嗯滴的基本都 2026-03-27 | 8/400 |
|
|
|
[考研] 材料專碩調(diào)劑 +11 | 椰椰。 2026-03-29 | 11/550 |
|
|
|
[考研] 0703本科鄭州大學(xué)求調(diào)劑 +7 | nhj_ 2026-03-25 | 7/350 |
|
|
|
[考研] 299求調(diào)劑 +10 | 15188958825 2026-03-25 | 10/500 |
|
|
|
[考研] 一志愿北京理工大學(xué)本科211材料工程294求調(diào)劑 +8 | mikasa的圍巾 2026-03-28 | 8/400 |
|
|
|
[考研] 343求調(diào)劑 +5 | 愛(ài)羈絆 2026-03-28 | 5/250 |
|
|
|
[考研] 材料與化工（0856）304求B區(qū)調(diào)劑 +8 | 邱gl 2026-03-27 | 8/400 |
|
|
|
[考研] 340求調(diào)劑 +5 | jhx777 2026-03-27 | 5/250 |
|
|
|
[考研] 348求調(diào)劑 +4 | 小懶蟲(chóng)不懶了 2026-03-27 | 5/250 |
|
|
|
[論文投稿] Journal of Mechanical Science and Technology +3 | Russ_ss 2026-03-25 | 5/250 |
|
|
|
[考研] 機(jī)械學(xué)碩310分，數(shù)一英一，一志愿211本科雙非找調(diào)劑信息 +3 | @357 2026-03-25 | 3/150 |
|
|
|
[考研] 281求調(diào)劑 +6 | Koxui 2026-03-24 | 7/350 |
|
|
|
[考研] 293求調(diào)劑 +7 | 加一一九 2026-03-24 | 7/350 |
|
|
|
[考研] 一志愿北化315 求調(diào)劑 +3 | akrrain 2026-03-24 | 3/150 |
|